ERBB2 and breast carcinoma: TNBCs are immunohistologically characterized by lack of estrogen receptor (ER) and progesterone receptor (PR) as well as human epidermal growth factor receptor 2 (HER2) amplification, and ~20% of all breast cancers are identified as TNBCs [1].